An interventional study of VitaFlow Liberty and Commercially available surgical bioprosthetic valve in Aortic Stenosis and Bicuspid Aortic Valve (BAV), sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 6th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2025, is one of 37 with no phase, reaches primary completion later than 43 of the 50 other live ones, and was the 43rd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 452 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 490 across the 22 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai MicroPort CardioFlow Medtech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
Shanghai MicroPort CardioFlow Medtech Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
MicroPort Scientific Corporation has 9 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of the Transcatheter aortic valve and retrievable delivery system (VitaFlow Liberty®) for the treatment of severe bicuspid aortic valve (BAV) stenosis.
Transcatheter aortic valve replacement (TAVR) has emerged as the first-line treatment for symptomatic severe AS currently, while TAVR for bicuspid aortic valve (BAV) stenosis has not been well demonstrated in randomized controlled trials, thus more randomized controlled studies of TAVR vs. SAVR are still needed to provide strong evidence that TAVR treatment for patients with BAV stenosis has good safety and effectiveness.
This study is a prospective, international multicenter, randomized controlled, non-inferiority clinical study, in which the study device (VitaFlow Liberty®) for TAVR is to be demonstrated as non-inferior to the control device (a commercially available surgical bioprosthetic valve) for SAVR in terms of the incidence of composite endpoint events (all-cause mortality, all strokes and re-hospitalizations) at 12 months postoperatively.
In this study, 452 eligible subjects will be randomly assigned to the study group (n=226) or the control group (n=226) in a 1:1 ratio. The subjects in study group will be treated with the TAVR surgery using the study device (VitaFlow Liberty®) , while the subjects in control group will be treated with the SAVR surgery using the control device (a commercially available surgical bioprosthetic valve), and clinical follow-ups will be performed at discharge (or 7 days after surgery), 30 days, 6 months, 12 months, and 2, 3, 4, 5 years after surgery, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAVR with the study device will be performed in the TAVR group
Device: VitaFlow Liberty
SAVR with a commercially available surgical bioprosthetic valve will be performed in the control group
Device: Commercially available surgical bioprosthetic valve
All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty
All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
Incidence of composite endpoint events (all-cause mortality, all strokes, and re-hospitalizations [surgery, valve or heart failure related re-hospitalizations])
The composite endpoint event at 12 months postoperatively refers to all-cause mortality, all strokes, and re-hospitalizations related to procedure, valve or heart failure that occur within 12 months postoperatively.
Time frame: 12 months postoperatively
Device success rate
Device success is defined as meeting all the following criteria: 1. Correct positioning of a single prosthetic heart valve into the proper anatomical location; 2. Successful access, delivery of the device, and retrieval of the delivery system; 3. Freedom from mortality; 4. Freedom from surgery or intervention related to the devicea or to a major vascular or access-related or cardiac structural complication; 5. Intended performance of the valvec (mean gradient \<20mmHg, peak velocity \<3 m/s, Doppler velocity index ≥ 0.25, and less than moderate aortic regurgitation).
Time frame: 30 days postoperatively
Prosthetic valve performance evaluation
The prosthetic valve performance will be evaluated independently by the corelab based on the echocardiography.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
New York Heart Association grading assessment of cardiac function
New York Heart Association (NYHA) grading system includes four gradings with higher grading means severer outcome.
Time frame: Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively
Quality of life assessment (Kansas City Cardiomyopathy Questionnaire score)
Kansas City Cardiomyopathy Questionnaire (KCCQ) score is ranged from 0 to 100 with higher score means better quality of life.
Time frame: 30 days, 6 months, 12 months postoperatively
All-cause mortality
According to the VARC3 criteria, all-cause mortality includes cardiovascular mortality and non-cardiovascular mortality.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of all strokes
According to the VARC3 criteria, all strokes include ischemic strokes (including TIAs), hemorrhagic strokes, and unspecified strokes, as well as disabling and non-disabling strokes.
Time frame: 30 days, 6 months, 12 months, 2 to 5 years postoperatively
Incidence of myocardial infarction
Myocardial infarction in this study is defined according to the VARC3 criteria.
Time frame: Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of major adverse cardiovascular and cerebrovascular events (MACCE)
MACCE includes all-cause mortality, myocardial infarction, all strokes, and reoperation due to valvular dysfunction, with each event defined according to the VARC3 criteria.
Time frame: 30 days, 6 months, 12 months postoperatively
Incidence of life-threatening or disabling major bleeding
Life-threatening or disabling major bleeding is defined as types 3 and 4 bleeding according to the VARC3 criteria.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of acute kidney injury (AKI)
According to the VARC3 criteria, AKI is defined as stages 2-4 acute kidney injury.
Time frame: Discharge, 30 days postoperatively
Incidence of conduction disturbance and arrhythmias
Conduction disturbance and arrhythmias are defined according to the VARC3 criteria.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of permanent pacemaker implantation
Defined as the percentage of subjects with newly permanent pacemaker implantation occurring after surgery among all subjects enrolled in each group.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of serious vascular complications
Serious vascular complications are defined according to the VARC3 criteria.
Time frame: 30 days, 6 months, 12 months postoperatively
Incidence of other TAVR-related complications
Other TAVR-related complications include: conversion to surgery, unplanned cardiopulmonary mechanical assistance, coronary artery occlusion requiring intervention, ventricular septal perforation, mitral valve damage or dysfunction, cardiac tamponade, endocarditis, valvular thrombosis, valvular dyslocation (displacement, embolization, false release), and reoperation due to valve dysfunction (including surgical or interventional therapy).
Time frame: Immediately, 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of Bioprosthetic valve dysfunction (BVD)
BVD includes structural valve deterioration (SVD), moderate and severe prosthesis-patient mismatch (PPM), moderate and severe paravalvular leak (PVL), thrombosis or endocarditis.
Time frame: 12 months, 2-5 years postoperatively
Moderate to severe structural valvular deterioration (HVD)
Moderate HVD is defined as an increase in mean transvalvular gradient ≥ 10mmHg resulting in mean gradient ≥ 20mmHgc with concomitant decrease in EOA ≥ 0.3cm2 or ≥ 25% and/or decrease in Doppler velocity index ≥ 0.1 or ≥ 20% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence or increase of ≥ 1 graded of intraprosthetic AR resulting in ≥ moderate AR. Severe HVD is defined as an increase in mean transvalvular gradient ≥ 20mmHg resulting in mean gradient ≥ 30mmHgc with concomitant decrease in EOA ≥ 0.6cm2 or ≥50% and/or decrease in Doppler velocity index ≥0.2 or ≥40% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence, or increase of ≥ 2 grades,d of intraprosthetic AR resulting in severe AR
Time frame: 12 months, 2-5 years postoperatively
Bioprosthetic valve dysfunction (BVF)
BVF is a composite endpoint, including severe HVD, aortic valve reintervention, and valve-related mortality (investigator assessment).
Time frame: 12 months, 2-5 years postoperatively
Re-hospitalization related to procedure, valve or heart failure
Re-hospitalization related to procedure, valve or heart failure is defined according to the VARC3 criteria.
Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively
Incidence of adverse events (AEs)
An AE is an untoward medical occurrence during the course of the clinical study, regardless of whether or not related to the study device
Time frame: throughout the clinical study period
Incidence of serious adverse events (SAEs)
Serious adverse event (SAE) refers to any adverse event that occurs during the clinical study of a medical device that results in any of the following: 1. Leads to death, or 2. Leads to serious deterioration of the health conditions, including: Fatal disease or injury Permanent defect in the physical structure or physical function Requiring hospitalization or prolongation of hospital stay Any event which requires medical or surgical intervention to prevent persistent disability/incapacity 3. Leads to fetal distress, fetal death or congenital abnormality or congenital defect, etc. Note: Planned hospitalizations due to pre-existing disease conditions, or events that do not result in significant deterioration in health status due to procedures required by the clinical study program are not considered SAEs.
Time frame: throughout the clinical study period
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 36 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. →